Skip to main content
BioVaxys Technology Corp. logo

BioVaxys Technology Corp. — Investor Relations & Filings

Ticker · BIOV ISIN · CA09076M2004 LEI · 894500UD22QWRLZYJ229 CSE Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2024-05-11 Regulatory Filings
Country CA Canada
Listing CSE BIOV

About BioVaxys Technology Corp.

https://biovaxys.com/

BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company specializing in the development and out-licensing of novel immunotherapy assets. The core technology is the proprietary DPX™ platform, a unique lipid-in-oil formulation designed for sustained, targeted immune responses. DPX forces active uptake into immune cells and lymph nodes, avoiding systemic side effects common to conventional delivery methods. The platform is versatile, supporting peptides, proteins, mRNA, and small molecules, and is being applied across oncology, infectious disease, allergy, and autoimmune disorders. The lead clinical asset, Maveropepimut-S (MVP-S), has demonstrated promising Phase 2B results in recurrent ovarian cancer and relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL). The company is also integrating Artificial Intelligence to enhance immunotherapeutic discovery.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2024-05-11 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings Classification · 95% confidence The document is titled 'Form 45-106F1 Report of Exempt Distribution' and contains detailed information about a securities distribution, including issuer details, underwriter information, distribution dates, types of securities distributed, purchaser information, compensation details, and regulatory references to Canadian securities laws (NI 45-106). This form is a regulatory filing used to report exempt distributions of securities, typically filed with Canadian securities regulators. It is not an annual report, earnings release, or any other financial report but a specific regulatory disclosure about securities distribution. The document is comprehensive and contains substantive data about the distribution, not merely an announcement or certification. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory disclosures that do not fit other specific categories.
2024-05-08 English
Material change report - English.pdf
Board/Management Information Classification · 95% confidence The document is a FORM 51-102F3 MATERIAL CHANGE REPORT, which is a regulatory filing used to disclose material changes in a company. The content specifically announces the appointment of a new Chief Financial Officer, Christopher Cherry. This is an announcement of a change in senior management, not a full report or financial statement. The document length is short (1868 characters), and it focuses on management change details. Therefore, it fits the category of Board/Management Information (MANG).
2024-05-07 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the closing of the first tranche of a private placement financing by BioVaxys Technology Corp. It details the number of units issued, the price, the use of proceeds, and regulatory compliance related to the securities issuance. There is no financial statement data, no detailed financial performance, no management discussion of results, no audit information, and no regulatory certification. The content focuses on capital raising activity and financing terms. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the financing event, not just an announcement of a report publication or a regulatory filing. Confidence is high due to clear and explicit content about private placement closing and financing details.
2024-05-04 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a bi-weekly status update regarding a Management Cease Trade Order (MCTO) issued by the Ontario Securities Commission due to the company's delay in filing its audited annual financial statements and interim financial statements. It references regulatory policies and filing deadlines but does not contain the actual financial statements or detailed financial data. The document is an update on the status of regulatory compliance and filing delays rather than the filings themselves. It is a regulatory announcement about the status of filings and compliance with securities regulations, fitting best into the category of Regulatory Filings (RNS).
2024-05-02 English
News release - English.pdf
Regulatory Filings
2024-04-30 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.